FX Solutions today announced that it received FDA 510(k) clearance for its lateralized and augmented glenoid baseplates.
The glenoid baseplates are available in 24 mm options with additional lateralization, augments and lateralized augments. The lateralized glenoid baseplates are available with a central screw or central post option and the augmented glenoid baseplates are available with the central screw option only.
FX Solutions’s Humelock glenoid baseplate is a 24 mm round baseplate with four baseplate options. Lateralization and augmentation are added under the flat surface of the baseplates and above the post, according to the company.
“As we continue to grow the FX portfolio, we evolve ever closer to providing a tailor-made approach for surgeons using our portfolio. They may be able to adapt the system to the patient rather than the patient to our system. This clearance of the lateralized and augmented glenoid baseplates is truly significant for our portfolio and the treatment of patients’ shoulders,” CEO Baptiste Martin said in a news release.
The company said it will include upgrades of its current instrumentation with the launch of the lateralized glenoid baseplates. The updates will include a trialing system for the reverse glenoid construct that features a monobloc trial with the glenosphere and lateralized glenoid baseplate together to replicate the feel of definitive implants.